Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04856566
Other study ID # HHC-2020-0368
Secondary ID DTNH2216C00022
Status Active, not recruiting
Phase Early Phase 1
First received
Last updated
Start date July 28, 2021
Est. completion date April 2024

Study information

Verified date May 2023
Source Yale University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Alcohol and Cannabis (CNB) are two of the most widely used intoxicants. The effects of driving while intoxicated on alcohol are well documented, resulting in numerous drunken driving laws and regulations. As CNB begins to be decriminalized, medical CNB use allowed in multiple U.S. states, and perception of harmfulness falls, CNB use is predicted to rise and it will become increasingly common to publicly encounter persons who recently used the drug. An area of potentially high concern is if ever-greater numbers of CNB users and its legalization will increase the risk of driving while intoxicated from recent CNB use, thereby increasing the risks to public safety. This study aims to examine the combined effects of smoking marijuana and drinking alcohol on simulated driving.


Description:

Alcohol is one of the most widely used substances. The effects of driving while intoxicated are well documented, leading to laws and regulations behind drunk driving. Marijuana is also a commonly abused drug. Marijuana use is not specific to social class, is linked to cognitive impairment and may be the cause of intoxication-induced accidents. The effects of marijuana intoxication on driving impairments are less documented. Data is being gathered in regards to this risk from our Neuroscience of Marijuana Impaired Driving study. The principle investigator's previous research includes the Brain and Alcohol Research with College Students (BARCS) study along with additional epidemiological studies reveal that most marijuana smokers also consume alcohol when they are intoxicated. These drugs interact pharmacodynamically and change each other's levels in the user's blood. They both have deleterious effects on driving. These effects are not additive but rather multiplicative. Someone using both substances will show more deleterious effects than someone using just one of these substances. This study will aim to investigate the brain and behavior in the same individuals, using a similar design to the NHTSA: Examine the Feasibility of a Standardized Field Test for Marijuana Impairment study. This structure coupled with past alcohol driving studies (Marijauna and Alcohol Impaired Driving) uses similar techniques of other measures of drunk driving. We hypothesize that alcohol and marijuana use combined will lead to greater impairment in a simulated driving task, as well as other driving related cognitive impairments. This study will aim to study feasible roadside sobriety tests for marijuana impairment. The study will consist of 5 days (screening visit and 4 dose visit days). In a randomized, counterbalanced, double-blind study, investigators will dose participants with alcohol to a legal amount of 0.05% blood alcohol content on 3 study days and dose to 0.08% blood alcohol content on 1 study day. Then investigators will administer high THC marijuana, low THC marijuana or placebo marijuana using paced inhalation through a vaporizer. Participants will include 12 regular alcohol consumers aged 21 to 40 years of age; all participants must report smoking and drinking together. Following this dosing, investigators will assess impairment through cognitive testing as well as a simulated driving test and neuropsychological tests. Samples of blood will also be collected at multiple time points throughout the study visits to be measured for THC concentration and its metabolites. This allows clarification between the relationship of impairment, as well as subjective and objective intoxication, and levels of THC and it's metabolites in the users system.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 12
Est. completion date April 2024
Est. primary completion date April 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years to 40 Years
Eligibility Inclusion Criteria: - Must have a driver's license; recent 2 years highway driving experience - Cannabis use for at least the past 2 years and report of getting high when smoking cannabis to avoid recruiting novice/inexperienced users. - Reports regularly drinking and smoking (does not need to be at the same time) - Use cannabis at least 5 times within life up to daily use, with occasional day of abstinence with no symptoms of craving or withdrawal. Exclusion Criteria: - Pregnancy, breastfeeding, and ineffective birth control methods. - Current severe substance use disorder (except cannabis and tobacco substance use disorders) - history of adverse effects with cannabis use - serious medical, neuro-ophthalmological, or neurological illness (i.e. cancer, seizure disorders, encephalopathy) - current diagnosis of any DSM-5 psychiatric disorder - prior diagnosis of any DSM-5 psychiatric disorder - report of any psychotic disorder in a first-degree relative - history of head trauma with loss of consciousness > 30 minutes or concussion lasting 30 days. - any medical/neurological condition that could compromise neurocognitive performance (i.e. epilepsy, multiple sclerosis, fetal alcohol syndrome) - recovering alcoholics or anyone currently abstaining from alcohol.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Low Marijuana, Hash, THC, or Grass
Cannabis with low amount of THC
High Marijuana, Hash, THC, or Grass
Cannabis with high amount of THC
Placebo
Placebo drug with no THC
0.05 BAC Alcohol
Amount of alcohol when consumed leads to BAC of 0.05
0.08 BAC Alcohol
Amount of alcohol when consumed leads to BAC of 0.08

Locations

Country Name City State
United States Hartford Hospital Hartford Connecticut

Sponsors (4)

Lead Sponsor Collaborator
Yale University Hartford Hospital, National Highway Traffic Safety Administration (NHTSA), National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Marijuana and alcohol induced performance changes on Cogstate 1-back/2-back task. The Cogstate 1-back/2-back task assesses working memory, it will be administered prior to dosing and at various time points after dosing. Baseline and post drug administration at: 10 min; 1.5 hours 2.5 hours
Primary Marijuana and alcohol induced performance changes on the Cogstate Social/Emotional Cognition Task. The Cogstate Social/Emotional Cognition task assesses emotional processing, it will be administered prior to dosing and at various time points after dosing. Baseline and post drug administration at: 10 min; 1.5 hours 2.5 hours
Primary Marijuana and alcohol induced performance changes on Cogstate Card Learning. The Cogstate Card Learning task assesses visual memory, it will be administered prior to dosing and at various time points after dosing. Baseline and post drug administration at: 10 min; 1.5 hours 2.5 hours
Primary Marijuana and alcohol induced performance changes on Groton Maze Learning task. The Cogstate Groton Maze Learning task assesses spatial learning and memory, it will be administered prior to dosing and at various time points after dosing. Baseline and post drug administration at: 10 min; 1.5 hours 2.5 hours
Primary Marijuana and alcohol induced performance changes on Alertmeter. The Alertmeter task assess visual judgment and alertness, it will be administered prior to dosing and at various time points after dosing. Baseline and post drug administration at: 10 min; 1.5 hours 2.5 hours
Primary Marijuana and alcohol induced performance changes on the Time Estimation task. The Time Estimation Task assesses timing, it will be administered prior to dosing and at various time points after dosing. Baseline and post drug administration at: 10 min; 1.5 hours 2.5 hours
Primary Marijuana and alcohol induced performance changes on the Go-No-Go task. The Go-No-Go task assesses inhibitory processing, it will be administered prior to dosing and at various time points after dosing. Baseline and post drug administration at: 10 min; 1.5 hours 2.5 hours
Primary Marijuana and alcohol induced performance changes on the Ramaeker's Critical Tracking Test. The Raemaker's Critical Tracking Test assesses hand eye coordination and visuomotor tracking, it will be administered prior to dosing and at various time points after dosing. Baseline and post drug administration at: 10 min; 1.5 hours 2.5 hours
Primary Marijuana and alcohol induced performance changes on the ANAM Pursuit Tracking Task. The ANAM Pursuit Tracking Task assesses hand eye coordination, it will be administered prior to dosing and at various time points after dosing. Baseline and post drug administration at: 10 min; 1.5 hours 2.5 hours
Primary Marijuana and alcohol induced performance changes on the Finger to Nose Task. The Finger to Nose Task assesses general motor coordination, it will be administered prior to dosing and at various time points after dosing. Baseline and post drug administration at: 10 min; 1.5 hours 2.5 hours
Primary Marijuana and alcohol induced performance changes on the One Leg Stand Task. The One Leg Stand Task assesses general motor coordination, it will be administered prior to dosing and at various time points after dosing. Baseline and post drug administration at: 10 min; 1.5 hours 2.5 hours
Primary Marijuana and alcohol induced performance changes on the Line Walking/Months Backwards Task. The Line Walking/Months Backwards Task assesses general motor coordination plus distraction, it will be administered prior to dosing and at various time points after dosing. Baseline and post drug administration at: 10 min; 1.5 hours 2.5 hours
Primary Marijuana and alcohol induced performance changes on the Time Reproduction Task. The Time Reproduction Task assesses general motor coordination plus timing, it will be administered prior to dosing and at various time points after dosing. Baseline and post drug administration at: 10 min; 1.5 hours 2.5 hours
Primary Marijuana and alcohol induced performance changes on the Ipod Balance Task. Participants will have an elastic wrap around their hips with an Ipod attached via durable velco. They will be asked to stand with both feet flat on the ground, looking ahead at a fixed point on the wall for 30 seconds, as well as 30 seconds with eyes closed. The amount of body sway will be measured using the accelerometer in an Ipod. Baseline and post drug administration at: 10 min; 1.5 hours 2.5 hours
Primary Marijuana and alcohol induced performance changes on the Ipod Punching Task. Participants will have an elastic wrap around their forearm with an Ipod attached via durable velrco. They will be asking to punch their arm forward while seated in a chair to measure their peak velocity of punching through the accelerometer in the Ipod. Baseline and post drug administration at: 10 min; 1.5 hours 2.5 hours
Primary Marijuana and alcohol induced performance changes on the DRUID tasks. DRUID is an application that has been designed to measure cognitive and behavior impairment following ingestion of drugs such as alcohol or marijuana. DRUID includes four Tasks to measure performance. The tasks are based on research on driving impairment and take about 5 minutes to complete. These tasks include a Reaction Time/Decision Making/DAT in which the subject has to press in two different locations on the Ipod screen dependent on which target shape appeared. The second task is a Reaction Time/Time Estimation/DAT task in which the subjects has to internally count up to 60 seconds while also touching the screen each time a target shape appears on the screen. The third task is a Motor Tracking/DAT tasks in which the subject must keep their finger on a moving circle on the screen. The last task is a balance task in which the subject is told to stand on one foot with the Ipod in an opposite hand keeping it as still as possible. Baseline and post drug administration at: 10 min; 1.5 hours 2.5 hours
Secondary Change in concentration of THC/metabolites in blood samples. Blood samples with be collected at 3 times throughout each day to assess for changes of THC and its metabolite levels. Baseline and post drug administration at: 30 min; 2.5 hours
Secondary Change in concentration of THC/metabolites in oral fluid tested using Quantisal Oral Fluid Collection devices. Oral fluid samples with be collected at 3 times throughout each day to assess for changes of THC and its metabolite levels. Baseline and post drug administration at: 30 min; 2.5 hours
Secondary Change in performance on simulated driving Road Tracking Task. The Road Tracking Task measures operational control of the vehicle. Operational control is measured by standard deviation of lane position from the center point of the lane. Post drug administration at: 30 min; 2.5 hours, 5 hours
Secondary Change in performance on simulated driving Car Following Task. The Car Following Task measures tactical control of the vehicle. Tactical control of the vehicle is measured by following distance from a lead vehicle. Post drug administration at: 30 min; 2.5 hours, 5 hours
Secondary Change in performance on simulated driving Gap Acceptance Task. The Gap Acceptance Task measures strategic control of the vehicle. Strategic control of the vehicle is measured by size of headway gaps that the participant chooses in pulling out into oncoming traffic to overtake a stopped car. Post drug administration at: 30 min; 2.5 hours, 5 hours
See also
  Status Clinical Trial Phase
Completed NCT02757313 - Neuroscience of Marijuana Impaired Driving Phase 1
Completed NCT03191084 - Examine the Feasibility of a Standardized Field Test for Marijuana Impairment: Laboratory Evaluations Early Phase 1
Active, not recruiting NCT05115513 - Standardized Field Test for Marijuana Impairment II Phase 1